SinoHub, Inc. (AMEX:SIHI) a rapidly-growing electronics company in the People's Republic of China, engaged in electronic component sales (ECP), private label, custom design mobile phone manufacturing and sales (VCM), and supply chain management (NYSE:SCM) services, announced that it has received initial orders for two new 2.75G phone models from HT Mobile, with shipments to commence in December 2010. HT Mobile has given indications to SinoHub that it anticipates ordering between 200,000 and 300,000 units of each model from during 2011.
SinoHub, Inc., founded in 2000 by veteran entrepreneur Harry Cochran and electronics industry veteran Lei Xia to play a part in the electronics revolution in China, provides virtual contract manufacturing, electronic component purchasing, and world-class supply chain management services with transparent information access for participants in the electronic components supply chain in China.
Power3 Medical Products, Inc. (OTC:PWRM)
PWRM, a bio-technology company, engages in the development and marketing of diagnostic tests in the fields of cancer, and neurodegenerative and neuromuscular diseases in the United States. PWRM’s products include BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer; and NuroPro, a serum test for the detection of neurodegenerative diseases, such as amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease. PWRM’s products analyze proteins and their mutations to assess an individual’s risk for developing disease later in life or a patient’s likelihood of responding to a particular drug; assess a patient’s risk of disease progression and disease recurrence; and measure a patient’s exposure to drug therapy. PWRM was formerly known as Surgical Safety Products, Inc. and changed its name to Power3 Medical Products, Inc. in September 2003. PWRM was founded in 1992 and is based in The Woodlands, Texas.
Power3 Medical Products Inc. has signed a definitive agreement recently to acquire all of the stock of Rozetta-Cell Life Sciences, Inc. PWRM plans to effectuate the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into PWRM, with PWRM remaining as the surviving company in the merger.
Rozetta-Cell is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. The company has a robust intellectual property portfolio and has created numerous products for adult stem cell therapy that are ready for market globally. Rozetta-Cell also has several collaborations in process through which it is partnering with industry-leading adult stem cell research companies and adult stem cell vendors.
To learn more about PWRM visit: http://www.Power3Medical.com
Neuberger Berman Real Estate Securities Income Fund Inc. (AMEX:NRO) has announced a distribution declaration of $0.02 per share of common stock. The distribution announced is payable on December 31, 2010, has a record date of December 15, 2010 and an ex-date of December 13, 2010. Under its level distribution policy, the Fund anticipates that it will make regular monthly distributions, subject to market conditions, of $0.02 per share common stock, unless further action is taken to determine another amount. There is no assurance that the Fund will always be able to pay a distribution of any particular size, or that a distribution will consist of only net investment income. The Fund’s ability to maintain its current distribution rate will depend on a number of factors, including the stability of income received from its investments, availability of capital gains, the cost of leverage and the level of other Fund expenses.
Neuberger Berman Group LLC is one of the world’s leading independent, employee-controlled asset management companies. As of September 30, 2010, assets under management were approximately $180 billion. Established in 1939, Neuberger Berman is a leader in a broad range of global investment solutions – equity, fixed income, and alternatives – to institutions and individuals through customized separately managed accounts, mutual funds and alternative investment products.
IDO Security Inc. (OTCPK:IDOI)
IDO Security Inc. engages in the design, development, and marketing of devices for the homeland security and loss prevention markets. IDOI's products are used in security screening procedures to detect ferrous and non-ferrous metallic objects concealed on or in footwear, ankles, and feet through the use of electro-magnetic fields. IDOI offers MagShoe that responds to the need for conducting a personal screening of the shoes and ankle area, without the need for removing shoes. IDOI's devices are used for the detection of metallic items during security screenings and at security checkpoints in venues, such as airports, prisons, educational institutions, schools, stadiums, commercial aviation and maritime facilities, rail transportation, shopping centers/places of entertainment, business facilities, bus and train stations, border crossings, government institutions/buildings, critical infrastructure, defense facilities, and other public locations requiring individual security screening. IDOI is based in New York, New York.
IDO Security, Inc., developer of the innovative MagShoe shoe scanning device (NYSE:SSD), continues to market its patented shoe scanning device (SSD), MagShoe 3G series across the globe. The MagShoe not only provides a safe and secure shoes-on weapons metal detection solution that can be easily incorporated to existing screening devices, but also provides a system that is comfortable and convenient for travelers.
To learn more about IDOI visit: http://www.idosecurityinc.com
Protalix BioTherapeutics, Inc. (AMEX:PLX) and Pfizer Inc. announced the submission of a Marketing Authorization Application to the European Medicines Agency for taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD)for the treatment of Gaucher disease. Taliglucerase alfa was granted Orphan Designation by the European Commission for the treatment of Gaucher disease on March 23, 2010.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system primarily in the United States.
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE) has received five thousand dollars in cash from a third party (D&G Group) for 1 (one) day of advertising services for IDO Security Inc. (OTCPK:IDOI). Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).